We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-9.26%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$321M
AUM Growth
-$44.2M
Cap. Flow
+$330K
Cap. Flow %
0.1%
Top 10 Hldgs %
50.52%
Holding
83
New
10
Increased
22
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
TSVT
2seventy bio
TSVT
+$6.24M
2
CYTK icon
Cytokinetics
CYTK
+$4.89M
3
AXGN icon
Axogen
AXGN
+$4.18M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$3.04M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$2.59M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$24.1M
2
SAGE
Sage Therapeutics
SAGE
+$8.48M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$5.93M
4
LYRA
LYRA THERAPEUTICS INC
LYRA
+$1.48M
5
RVMD icon
Revolution Medicines
RVMD
+$1.15M

Sector Composition

Rank Sector Weight
1 Healthcare 82.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.05M 1.26%
92,887
-1,813
-2% -$64.7K
RCUS icon
27
Arcus Biosciences
RCUS
$3.56B
$4M 1.24%
222,717
-3,000
-1% -$60.3K
VKTX icon
28
Viking Therapeutics
VKTX
$3.88B
$3.54M 1.1%
319,655
+26,000
+9% +$372K
ARAY icon
29
Accuray
ARAY
$33.8M
$3.32M 1.03%
1,222,358
– –
EWTX icon
30
Edgewise Therapeutics
EWTX
$4.78B
$2.98M 0.93%
519,384
– –
MDWD icon
31
MediWound
MDWD
$184M
$2.74M 0.85%
257,653
– –
IPSC icon
32
Century Therapeutics
IPSC
$343M
$2.61M 0.81%
1,307,407
– –
BCYC
33
Bicycle Therapeutics
BCYC
$278M
$2.45M 0.76%
122,200
– –
AMLX icon
34
Amylyx Pharmaceuticals
AMLX
$2.69B
$2.24M 0.7%
+122,547
New +$2.59M
PRCT icon
35
Procept Biorobotics
PRCT
$1.14B
$2.21M 0.69%
67,300
+59,300
+741% +$2.02M
ATXS
36
DELISTED
Astria Therapeutics
ATXS
$2.2M 0.69%
295,493
+167,840
+131% +$1.43M
AUTL
37
Autolus Therapeutics
AUTL
$532M
$2.16M 0.67%
928,253
-2,141
-0.2% -$6.1K
KROS icon
38
Keros Therapeutics
KROS
$211M
$2.1M 0.65%
65,961
+18,300
+38% +$683K
LKFT
39
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$2.08M 0.65%
60,175
+7,500
+14% +$292K
THRD
40
DELISTED
Third Harmonic Bio
THRD
$1.92M 0.6%
+300,000
New +$1.83M
BWAY
41
Brainsway
BWAY
$628M
$1.75M 0.54%
864,362
-145,000
-14% -$224K
RGLS
42
DELISTED
Regulus Therapeutics
RGLS
$1.52M 0.47%
1,111,049
– –
CMPS
43
Compass Pathways
CMPS
$1.83B
$1.43M 0.44%
+193,000
New +$1.71M
CERE
44
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$1.36M 0.42%
+62,200
New +$1.56M
IMGN
45
DELISTED
Immunogen Inc
IMGN
$1.32M 0.41%
+83,000
New +$1.38M
LRMR icon
46
Larimar Therapeutics
LRMR
$436M
$1.29M 0.4%
327,373
-23,000
-7% -$87K
SPRB
47
Spruce Biosciences
SPRB
$128M
$1.29M 0.4%
7,602
+3,442
+83% +$580K
MREO
48
Mereo BioPharma
MREO
$48.8M
$1.24M 0.39%
962,513
-46,500
-5% -$61.7K
GOSS icon
49
Gossamer Bio
GOSS
$87.2M
$1.23M 0.38%
+1,476,052
New +$1.7M
PRQR icon
50
ProQR Therapeutics
PRQR
$268M
$1.22M 0.38%
940,582
– –
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, DAFNA Capital Management held 83 positions worth $321M, down 12% from $366M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DAFNA Capital Management's Q3 2023 filing shows 10 new, 22 increased, 13 reduced and 8 closed positions. Its largest new stake was Amylyx Pharmaceuticals: 122,547 shares worth $2.24M. The largest sale was IVERIC bio, Inc. Common Stock, an estimated $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 83% a quarter earlier.

  • DAFNA Capital Management's largest Q3 2023 buy was Amylyx Pharmaceuticals: 122,547 shares worth $2.24M.
  • DAFNA Capital Management added most to 2seventy bio in Q3 2023, an estimated $6.24M increase.
  • DAFNA Capital Management's biggest Q3 2023 reduction was Revolution Medicines, cutting an estimated $1.15M.
  • DAFNA Capital Management fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $24.1M.
  • DAFNA Capital Management's ten largest holdings make up 51% of its $321M portfolio in Q3 2023.
  • DAFNA Capital Management opened 10 new positions and closed 8 in Q3 2023.
  • DAFNA Capital Management's portfolio value fell 12% quarter-over-quarter to $321M.

Based on DAFNA Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.